Irwin Naturals' Bold Leap: Cannabis, Psychedelics Drive Q3 Buzz Despite Falling Revenue & Surging Losses
Irwin Naturals' Bold Leap: Cannabis, Psychedelics Drive Q3 Buzz Despite Falling Revenue & Surging Losses
Irwin Naturals Inc. (CSE:IWIN) (OTC:IWINF) (FRA: 97X), a nutraceutical company leveraging its brand into the cannabis and psychedelics sectors, reported its financial results for the third quarter of fiscal 2023, revealing revenue of $19.1 million, down from $22.0 million in the same period last year and $22.1 million in the previous quarter.
Irwin Naturals Inc.（CSE: IWIN）（場外交易代碼：IWINF）（FRA：97X）是一家利用其品牌進入大麻和迷幻藥領域的營養品公司，公佈了2023財年第三季度的財務業績，收入爲1,910萬美元，低於去年同期的2,200萬美元和上一季度的2,210萬美元。
"During the first three quarters of 2023, we successfully launched our branded licensing initiative in our cannabis sector," Sean Sand, CFO, stated. "Sales have exceeded our expectations and we look forward to continuing our licensing efforts in the space. We also continued to expand our mental health footprint through the acquisition of an industry-leading marketing and patient acquisition platform, Ketamine Media, enabling greater treatment availability and market expansion."
首席財務官肖恩·桑德表示：“在2023年的前三個季度，我們在大麻領域成功啓動了品牌許可計劃。”“銷售超出了我們的預期，我們期待繼續在該領域開展許可工作。我們還通過收購行業領先的營銷和患者獲取平台****媒體，繼續擴大我們的心理健康影響力，從而提高治療可用性和市場擴張。”
Q3 Financial Highlights
第三季度財務摘要
-
Gross profit was $7.8 million, which compares to $10.6 million in the third quarter of 2022.
-
Net loss amounted to $1.96 million, versus net loss of $583,000 in the same period last year.
-
Income from operations decreased $2.9 million from $0.6 million in Q3 2022 to a loss of $2.3 million in Q3 2023. The decline is primarily attributed to the continued startup costs related to the company's 2022 and 2023 acquisitions via Irwin Naturals Emergence.
-
In the third quarter, the company sold the assets of underperforming clinics and shifted its focus to clinics that are wholly owned and operated by Irwin Naturals Emergence.
-
As of June 30, the company had $70.86 million in total assets and $56.97 million in total liabilities, compared to $78.8 million and $48.5 million, respectively, on December 31, 2022.
-
毛利爲780萬美元，而2022年第三季度爲1,060萬美元。
-
淨虧損爲196萬美元，而去年同期的淨虧損爲58.3萬美元。
-
運營收入從2022年第三季度的60萬美元減少290萬美元，至2023年第三季度的虧損230萬美元。下降的主要原因是與該公司在2022年和2023年通過Irwin Naturals Emergence進行收購相關的持續啓動成本。
-
在第三季度，該公司出售了表現不佳的診所的資產，並將其重點轉移到由Irwin Naturals Emergence全資擁有和運營的診所上。
-
截至6月30日，該公司的總資產爲7,086萬美元，總負債爲5,697萬美元，而2022年12月31日分別爲7,880萬美元和4,850萬美元。
Operational Highlights
運營亮點
During the first half of 2023, Irwin Naturals launched the first products to the continental cannabis market and signed ten brand licensing deals that will make THC-enhanced Irwin Naturals products available in places like California, Colorado, Mississippi, Michigan, New Mexico, Oregon, Oklahoma and Canada.
2023年上半年，Irwin Naturals向大陸大麻市場推出了首批產品，並簽署了十項品牌許可協議，這些協議將在加利福尼亞州、科羅拉多州、密西西比州、密歇根州、新墨西哥州、俄勒岡州、俄克拉荷馬州和加拿大等地提供四氫大麻酚增強型Irwin Naturals產品。
Additionally, to date, the company owns and operates five mental health clinics and one advertising company specializing in ketamine treatments. It will continue to build upon this solid foundation and make the necessary investments to support our growth objectives within the psychedelics sector.
此外，迄今爲止，該公司擁有並經營五家心理健康診所和一家專門從事****治療的廣告公司。它將繼續在這一堅實的基礎上再接再厲，進行必要的投資，以支持我們在迷幻藥領域的增長目標。
Related Links:
相關鏈接：
Irwin Naturals Revenue Sluggish In Q2, Net Loss Grows YOY
Irwin Naturals第二季度收入疲軟，淨虧損同比增長
Irwin Naturals Launches Trio Of Cannabis Tinctures In California
Irwin Naturals 在加利福尼亞推出三款大麻酊劑
Photo: Courtesy of Yash Lucid via Pexels
照片：由 Yash Lucid 通過 Pexels 提供
譯文內容由第三人軟體翻譯。